^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma

Published date:
02/03/2020
Excerpt:
...with EGFRT790M and EGFRC797S mutations, were highly responsive to the combined treatment of Notch inhibitors with gefitinib or osimertinib, respectively…
DOI:
10.1172/JCI126896